PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas

Yuan Ren, Chengfeng Bi, Xiaohong Zhao, Tint Lwin, Cheng Wang, Ji Yuan, Ariosto S. Silva, Bijal D. Shah, Bin Fang, Tao Li, John M. Koomen, Huijuan Jiang, Julio C. Chavez, Lan V. Pham, Praneeth R. Sudalagunta, Lixin Wan, Xuefeng Wang, William S. Dalton, Lynn C. Moscinski, Kenneth H. ShainJulie Vose, John L. Cleveland, Eduardo M. Sotomayor, Kai Fu, Jianguo Tao

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL) results in aggressive disease that is refractory to treatment. By integrating activity-based proteomic profiling and drug screens, polo-like kinase-1 (PLK1) was identified as an essential regulator of the MYC-dependent kinome in DHL. Notably, PLK1 was expressed at high levels in DHL, correlated with MYC expression, and connoted poor outcome. Further, PLK1 signaling augmented MYC protein stability, and in turn, MYC directly induced PLK1 transcription, establishing a feed-forward MYC-PLK1 circuit in DHL. Finally, inhibition of PLK1 triggered degradation of MYC and of the antiapoptotic protein MCL-1, and PLK1 inhibitors showed synergy with BCL-2 antagonists in blocking DHL cell growth, survival, and tumorigenicity, supporting clinical targeting of PLK1 in DHL.

Original languageEnglish (US)
Pages (from-to)5531-5548
Number of pages18
JournalJournal of Clinical Investigation
Issue number12
StatePublished - Dec 3 2018

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas'. Together they form a unique fingerprint.

Cite this